Exploring the Potential of Zein Nanoparticles in Personalised Cancer Therapy, Highlighting Their Various Methodologies, Applications and Challenges
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70752 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Hanan M Alharbi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. Hauptthemen laut MEDLINE: Zein, Nanoparticles, Precision Medicine, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Zein, a corn‐derived prolamine protein, has become a powerful ally in the fight against cancer, particularly non‐small cell lung cancer (NSCLC.) Its unique attributes, enriched by modifiable hydroxyl and amino groups, have led to the development of advanced functionalised drug delivery systems. Innovative techniques like chemical crosslinking, desolvation, dispersion and micromixing have led to the creation of zein‐based nanoparticles, revolutionising cancer therapy. Central to this examination is the remarkable ability of zein NPs to enhance drug stability, optimise oral bioavailability and improve targeted drug delivery, specifically tailored to combat NSCLC. This represents not just a technological breakthrough but a paradigm shift, ushering in a new era of precise, personalised and effective cancer treatment. Zein, a hydrophobic nanoparticle, is a promising drug for cancer treatment. However, its journey to the clinic is challenging due to its hydrophobic nature and the need for advanced evaluative platforms. This review emphasises the need for rigorous research to align zein's potential with real‐world applications. It offers a synthesis of methodologies, applications, and obstacles, aiming to see zein nanoparticles as a central element in cancer therapy innovations. The review encourages researchers, clinicians and industry professionals to embrace the potential of zein and promote the convergence of laboratory innovation and clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
- Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
- Postgraduate and Research Department of Biotechnology, St. Xavier's College (Autonomous), Kolkata, India.
- Department of Research Publications, Kampala International University, Kampala, Uganda.
- Department of Biochemistry, Faculty of Basic Medical Sciences, College of Medicine, Federal University of Health Sciences, Otukpo, Benue State, Nigeria.
- Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, India.
ORCID-Profile: Daniel Ejim Uti, Bikram Dhara
Zitieren
APA
Alharbi, H. M., Alqahtani, T., Alqalawi, N. A., Alsayegh, S. A., Almaghrabi, B. A., Sarkar, S., Uti, D. E., & Dhara, B. (2025). Exploring the Potential of Zein Nanoparticles in Personalised Cancer Therapy, Highlighting Their Various Methodologies, Applications and Challenges. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70752
Vancouver
Alharbi HM, Alqahtani T, Alqalawi NA, Alsayegh SA, Almaghrabi BA, Sarkar S, et al. Exploring the Potential of Zein Nanoparticles in Personalised Cancer Therapy, Highlighting Their Various Methodologies, Applications and Challenges. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70752
BibTeX
@article{Alharbi2025,
author = {Alharbi, Hanan M and Alqahtani, Taha and Alqalawi, Nada A and Alsayegh, Shayma A and Almaghrabi, Basmah A and Sarkar, Subham and Uti, Daniel Ejim and Dhara, Bikram},
title = {Exploring the Potential of Zein Nanoparticles in Personalised Cancer Therapy, Highlighting Their Various Methodologies, Applications and Challenges},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70752}
}
EUVIMED